NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report issued on Monday. The brokerage set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets dropped their price target on NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a research report on Monday, November 11th.

NovaBay Pharmaceuticals Price Performance

Shares of NBY stock opened at $0.73 on Monday. The company has a market cap of $3.60 million, a price-to-earnings ratio of -0.01 and a beta of 0.65. The stock has a 50 day simple moving average of $0.62 and a 200-day simple moving average of $0.77. NovaBay Pharmaceuticals has a 1-year low of $0.36 and a 1-year high of $9.08.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.